文献速递血液净化与透析

透析患者最佳血磷控制与冠状动脉钙化的关系

Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients.
PubMed 文献 · J Am Soc Nephrol · 2021-02-05

这项随机、开放标签、多中心、2×2析因试验纳入160名维持性透析成人,比较蔗糖氢氧化氧铁与碳酸镧两种非钙磷结合剂,以及严格(3.5-4.5 mg/dl)与标准(5.0-6.0 mg/dl)两种血磷目标对冠状动脉钙化(CAC)进展的影响。全分析集115例,两种磷结合剂间CAC评分百分比变化无显著差异,但严格组CAC评分百分比变化显著低于标准组(中位8.52 vs 21.8,P=0.006),该效应在65-74岁较20-64岁更明显(交互P=0.003)。

要点

  • 严格血磷目标(3.5-4.5 mg/dl)较标准目标(5.0-6.0 mg/dl)显著减缓透析患者CAC进展。
  • 蔗糖氢氧化氧铁与碳酸镧对CAC进展的影响无显著差异。
  • 严格控磷的获益在65-74岁患者中比20-64岁更明显。

核心结论

  • 严格血磷控制有望延缓维持性血液透析患者的冠状动脉钙化进展,但需更大样本研究进一步验证。

研究设计与样本

  • 随机、开放标签、多中心、2×2析因干预试验,纳入160名维持性透析成人,全分析集115例。

主要发现

  • 碳酸镧组与蔗糖氢氧化氧铁组CAC评分百分比变化无显著差异。
  • 严格组CAC评分百分比变化中位8.52(四分位距-1.0-23.9),显著低于标准组中位21.8(四分位距10.0-36.1),P=0.006。
  • 该效应在65-74岁较20-64岁更明显,交互P=0.003。
  • CAC评分绝对变化得到相似结果。

关键数值与推荐

  • 严格组血磷目标3.5-4.5 mg/dl,标准组5.0-6.0 mg/dl。
  • 主要终点为12个月治疗期间CAC评分百分比变化。

临床怎么用

  • 对维持性血液透析患者,可考虑将血磷控制在3.5-4.5 mg/dl以减缓CAC进展。
  • 非钙磷结合剂选择(蔗糖氢氧化氧铁或碳酸镧)对CAC进展影响未见显著差异。

局限性

  • 样本量有限(全分析集115例),需更大样本研究验证。
  • 开放标签设计可能引入偏倚。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In patients on maintenance dialysis, cardiovascular mortality risk is remarkably high, which can be partly explained by severe coronary artery calcification (CAC). Hyperphosphatemia has been reported to be associated with the severity of CAC. However, the optimal phosphate range in patients on dialysis remains unknown. This study was planned to compare the effects on CAC progression of two types of noncalcium-based phosphate binders and of two different phosphate target ranges. METHODS: We conducted a randomized, open-label, multicenter, interventional trial with a two by two factorial design. A total of 160 adults on dialysis were enrolled and randomized to the sucroferric oxyhydroxide or lanthanum carbonate group, with the aim of reducing serum phosphate to two target levels (3.5-4.5 mg/dl in the strict group and 5.0-6.0 mg/dl in the standard group). The primary end point was percentage change in CAC scores during the 12-month treatment. RESULTS: The full analysis set included 115 patients. We observed no significant difference in percentage change in CAC scores between the lanthanum carbonate group and the sucroferric oxyhydroxide group. On the other hand, percentage change in CAC scores in the strict group (median of 8.52; interquartile range, -1.0-23.9) was significantly lower than that in the standard group (median of 21.8; interquartile range, 10.0-36.1; P=0.006). This effect was pronounced in older (aged 65-74 years) versus younger (aged 20-64 years) participants (P value for interaction =0.003). We observed a similar finding for the absolute change in CAC scores. CONCLUSIONS: Further study with a larger sample size is needed, but strict phosphate control shows promise for delaying progression of CAC in patients undergoing maintenance hemodialysis. CLINICAL TRIAL REGISTRY NAME AND REGISTRATION NUMBER: Evaluate the New Phosphate Iron-Based Binder Sucroferric Oxyhydroxide in Dialysis Patients with the Goal of Advancing the Practice of EBM (EPISODE), jRCTs051180048.

来源:J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Isaka Y, Hamano T, Fujii H, et al. Optimal Phosphate Control Related to Coronary Artery Calcification in Dialysis Patients. J Am Soc Nephrol. 2021. PMID: 33547218. doi:10.1681/ASN.2020050598

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。